Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350676 | 0.86 | KMT2A (0.44) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL10144870 | 0.80 | DRD4 (0.60) | DRD4SLC6A12SLC6A13MEN1NPC1 | |
| SCHEMBL8346658 | 0.79 | DRD4 (0.64) | DRD4SLC6A12SLC6A13MEN1NPC1 | |
| SCHEMBL2339350 | 0.76 | HTR2A (0.54) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL10175644 | 0.76 | BCHE (0.47) | — | |
| SCHEMBL4082004 | 0.75 | GSTP1 (0.49) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL2097693 | 0.74 | HDAC3 (0.51) | KMT2ASMN1; SMN2 | |
| SCHEMBL21471527 | 0.74 | GSTP1 (0.51) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL2753551 | 0.73 | DRD4 (0.64) | DRD4SLC6A12SLC6A13NPC1MAPT | |
| SCHEMBL5020592 | 0.73 | P2RX3 (0.51) | MEN1NPC1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
| EP-1485348-B1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2003076395-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | DRD4 2961/4885SLC6A12 4568/4885SLC6A13 4834/4885 |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | DRD4 2961/4885SLC6A12 4568/4885SLC6A13 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.